First AD

Second AD

Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Gynecologic Oncology

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Updates in Treatment Approaches for Ovarian and Endometrial Cancers

Peer Exchange

UCLA Health Jonsson Comprehensive Cancer Center

Cancer Centers

Partner

Dana-Farber Cancer Institute

NYU Langone's Perlmutter Cancer Center

Washington University School of Medicine in St. Louis 

The University of Texas MD Anderson Cancer Center

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Efficacy of Subsequent Therapies in Advanced Ovarian Cancer

Frontline Maintenance Therapy in Ovarian Cancer

Ovarian Cancer: Deciding Between Treatment Options

Unmet Needs in the Maintenance Setting in Ovarian Cancer

Recent Data on PARP Inhibitors as First-Line Maintenance in Ovarian Cancer

Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer

Ongoing Trials on Maintenance Therapy in Recurrent Ovarian Cancer

MIRASOL Trial: Mirvetuximab in Platinum-Resistant Ovarian Cancer

Recently Presented Data on Endometrial Cancer

NRG-GY018 and RUBY Trials in Endometrial Cancer

The PHAEDRA Study and Clinical Trial Landscape in Endometrial Cancer

KEYNOTE-775: Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer

Ongoing Trials in Endometrial Cancer

Future Outlook for Treatment of Endometrial Cancer